H.R. 413: To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as ...

...provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

113th Congress, 2013–2015. Text as of Jan 23, 2013 (Introduced).

Status & Summary | PDF | Source: GPO

HR 413 IH

113th CONGRESS

1st Session

H. R. 413

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

IN THE HOUSE OF REPRESENTATIVES

January 23, 2013

Mr. WELCH (for himself, Mr. HANNA, Mr. COOPER, and Mr. BRALEY of Iowa) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

    Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. ELIMINATING THE 2-YEAR DELAY IN IMPLEMENTATION OF ORAL-ONLY ESRD-RELATED DRUGS IN THE MEDICARE ESRD PROSPECTIVE PAYMENT SYSTEM.

    Section 632(b) of the American Taxpayer Relief Act of 2012 (Public Law 112-240) is amended by striking all that precedes ‘With respect to the implementation’ and inserting the following::

    ‘(b) Monitoring of Implementation of Oral-Only ESRD-Related Drugs in the ESRD Prospective Payment System- With respect to the implementation’.